ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after...

ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpointHealth & Biotech
4 hours ago | Nadine McGrath

Positive journal publication for ImpediMed

Brisbane-based medical software technology company ImpediMed (ASX:IPD) got a lift during the week with a leading journal eClinicalMedicine, part of The Lancet Discovery Science, publishing Multinational Association of Supportive Care in Cancer (MASCC) guidelines, which specifically include bioimpedance spectroscopy (BIS) as a recommended option to identify early signs of lymphoedema.

IPD’s device the SOZO is the only FDA cleared and clinically validate BIS system for the early detection of lymphedema.

The MASCC guidance was generated by a global panel, including participants from Japan, USA, Hong Kong, Canada, Italy, Denmark, Australia, Spain and UK. IPD says the recommendations support its US and global sales efforts.

BIS for prevention of breast cancer-related lymphoedema is now included in the globally referenced NCCN Guidelines and MASCC Guidelines.

SOZO is available in the US, Australia, New Zealand, Hong Kong, UK, Ireland, Denmark and Sweden.

“It basically says from all the research that has been done one of the options is to use ImpediMed’s technology with the early detection of breast cancer-related lymphoedema,” Power says.

“That is a good piece of news and that share price has popped up a bit on the back of that because it’s really got hammered following their second quarter results which were below expectations.

“I must admit I was surprised at how far the share price got knocked but it’s clawing its way back now.”

Morgans has a speculative buy rating on IPD, reducing its 12-month target price from 22 cents to 20 cents following its Q2 Fy24 result.